Teva jumps after Wall Street upgrades, analysts say stock 'too cheap to ignore'

Wall Street analysts are turning bullish on Teva Pharmaceutical Industries.

UBS upgraded Teva to buy from neutral on Wednesday, saying its shares are "too cheap to ignore." Piper Jaffray also brought Teva's rating up a notch to neutral from underweight, seeing its new product Ajovy heading for "significant success."